Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 1835 results for carers

  1. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

  2. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

  3. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

  4. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

  5. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

  6. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  7. Service user experience in adult mental health services (QS14)

    This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.

  8. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  9. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

  10. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

  11. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

  13. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

  14. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development Reference number: GID-TA11015 Expected publication date: TBC

  15. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC